A ntiretroviral therapy (ART) has transformed HIV infection from a terminal disease to a manageable chronic illness. Although incidence of AIDS-defining conditions has decreased, it has increased for other comorbid conditions (1) , including osteoporosis and fragility fractures (2) (3) (4) (5) (6) (7) . Both viral and host factors-HIV infection mediated by certain viral proteins, HIVassociated inflammation, lifestyle and behavioral factors, underlying genetic predisposition, comorbid conditions, and ART-probably contribute to bone loss and fracture risk (8 -14) .
Studies of ART initiation have confirmed that 2% to 6% of hip and spine BMD is lost over the first 24 to 48 weeks after initiation, with subsequent stabilization (15) (16) (17) (18) . The magnitude of bone loss is similar to that seen with glucocorticoids or during the first year of menopausal transition (19, 20) . Initial loss is marked by an increase in serum bone resorption markers followed by a delayed compensatory increase in bone formation markers (21) ; therefore, this catabolic window, a high bone turnover state with excess resorption, may be a central mechanism of bone loss with ART initiation.
Tenofovir disoproxil fumarate (TDF), a nucleotide analogue reverse transcriptase inhibitor, has been associated with greater bone loss than other reverse transcriptase inhibitors (15, 16) . Use of TDF is associated with increased parathyroid hormone (PTH) (24, 25) . Efavirenz induces cytochrome P450 enzymes involved in vitamin D metabolism and may accelerate the catabolism of 25-(OH)D and 1,25-(OH) 2 D 3 , the latter being the active vitamin D metabolite (26) . These ART agents are combined with emtricitabine (FTC), a nucleoside analogue reverse transcriptase inhibitor, into a fixed-dose combination, once-a-day pill (EFV/FTC/TDF) that is highly effective for treating HIV (27) .
Beyond effects on bone metabolism, vitamin D has immunomodulatory effects mediated through the vitamin D receptor present on cells in both the innate and the adaptive immune system (28, 29) . Vitamin D increases monocyte expression of CD14 and cathelicidin, molecules involved in innate immune responses (30, 31) ; down-regulates cytokine expression in activated T cells; and suppresses T-cell proliferation and production of interferon-␥ and interleukin (IL)-2, thus reducing the net state of inflammation (32, 33) . These pathways are particularly relevant in HIV infection, in which excess monocyte and T-cell activation are important drivers of morbidity and mortality (34 -37) .
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We hypothesized that high-dose vitamin D and calcium supplementation would attenuate bone loss associated with initiation of EFV/FTC/TDF. In addition, we evaluated immunomodulatory effects of vitamin D in the setting of HIV treatment. We report the results of the AIDS Clinical Trials Group A5280 trial, a multicenter, randomized, double-blind, placebo-controlled study assessing the effect of daily oral doses of 4000 IU of vitamin D 3 and 1000 mg of calcium carbonate in adults with HIV initiating their first ART regimen with EFV/FTC/TDF.
METHODS
Patients with ART-naive HIV without evidence of resistance to the antiretrovirals in the regimen and with HIV-1 RNA levels greater than 1000 copies/mL were eligible if they met the following criteria: screening 25-(OH)D level between 25 and 188 nmol/L; creatinine clearance of 60 mL/min/1.73 m 2 or greater, estimated by the Cockcroft-Gault formula; and serum calcium level less than 2.6 mmol/L. We excluded patients with daily calcium supplementation greater than 500 mg, daily vitamin D supplementation greater than 800 IU, any bisphosphonate use, recent steroid or chemotherapy treatments, clinically active thyroid disease, active substance or alcohol abuse, history of fragility fracture, documented osteoporosis, nephrolithiasis, or weight greater than 136 kg (limit of the dual-energy x-ray absorptiometry [DXA] scanner). Pregnant and breastfeeding women were also excluded. We did 3-day dietary recalls at entry to estimate vitamin D and calcium intake. Patients were randomly assigned to 4000 IU of cholecalciferol (vitamin D 3 ) daily plus 500 mg of calcium carbonate twice daily or identically matching placebos (Tishcon) and were counseled to take with food to facilitate absorption. Some experts consider the current upper U.S. Dietary Reference Intake of 2000 IU to be below actual physiologic requirements; therefore, we tested the highest supplementation without risk for toxicity (38 -40) . A dose of 4000 IU of vitamin D 3 is the highest daily dose considered safe for adults by the Institute of Medicine (41) and has previously been evaluated in persons with HIV with excellent tolerability and safety data (42) . Patients were randomly assigned in a 1:1 ratio using permuted blocks stratified by screening serum 25-(OH)D levels (≤50 and >50 nmol/L). Randomization was done using Web-based access to a central computer system maintained by the Frontier Science & Technology Research Foundation (Buffalo, New York). The institutional review boards of all participating sites approved the study, and all patients provided written informed consent.
The primary end point was percentage of change in total hip BMD from baseline to 48 weeks. Secondary end points included percentage of change in lumbar spine BMD at 48 weeks, change in plasma 25-(OH)D and PTH levels, markers of bone turnover, soluble inflammatory biomarkers, and CD4 cell counts at 24 and 48 weeks. Incidence of hypercalcemia and nephrolithiasis was monitored. All DXA scans were read in a blinded fashion at the Body Composition Analysis Center at Tufts Medical Center (Boston, Massachusetts) using a standardized protocol.
Biomarker Assays
Screening was done at local laboratories certified by the Clinical Laboratory Improvement Amendments. Serum samples were stored at Ϫ70°C at the Irving Institute Biomarkers Core Laboratory at Columbia University Medical Center (New York, New York) and underwent batched analysis. We measured 25-(OH)D 2 and 25-(OH)D 3 by liquid chromatography-mass spectrometry, intact PTH by a radioimmunoassay (Scantibodies), procollagen-1 N-terminal peptide (P1NP) by a radioimmunoassay (Immunodiagnostic Systems), C-terminal telopeptide of type 1 collagen (CTX) by an enzyme-linked immunosorbent assay [ELISA] (Immunodiagnostic Systems), IL-6 by an ELISA (R&D Systems), soluble tumor necrosis factor-␣ receptor (sTNFR) by an ELISA (R&D Systems), and soluble CD14 by an ELISA (R&D Systems). Inflammatory biomarkers were chosen based on association with relevant end points (43) (44) (45) (46) . All biomarkers, except for 25-(OH)D, were measured in duplicate, and values were averaged for analysis.
Statistical Analysis
To provide an intention-to-treat analysis, evaluations were done regardless of treatment change or discontinuation. Two patients who did not have the correct vitamin D test done at baseline were excluded from the efficacy analyses. Stratified Wilcoxon rank-sum tests were used to evaluate for distribution shifts between the treatment groups, which were stratified by screening vitamin D levels. Fisher exact tests and Wilcoxon rank-sum tests were used to evaluate for differences between groups for categorical and continuous
EDITORS' NOTES Context
Patients with HIV who initiate antiretroviral therapy (ART) lose bone mineral density (BMD). The role of supplementation with vitamin D and calcium in preventing such loss is unknown.
Contribution
In a randomized clinical trial of patients with HIV who were initiating ART, BMD, 25-hydroxyvitamin D, parathyroid hormone, phosphate metabolism, and markers of bone turnover were measured at baseline. Patients who then received vitamin D 3 plus calcium along with ART had smaller declines in BMD of the hip and spine than those who received placebo along with ART.
Caution
Nearly all of the patients were men.
Implication
Supplementation with vitamin D and calcium may prevent bone loss in patients with HIV initiating ART.
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Vitamin D and Calcium Prevent ART-Related Bone Loss in Patients With HIV secondary outcomes, respectively. Wilcoxon signedrank tests were used to evaluate change within a treatment group. The 95% CIs for median changes within a group were estimated using a distribution-free method via percentiles. For the BMD outcomes, modification of the treatment effect by screening vitamin D stratum was evaluated by means of linear regression. Analyses of the primary outcomes of change in hip and spine BMD from baseline to 48 weeks used a multiple-imputation approach to fill in missing data with a Markov-chain Monte Carlo method. A prespecified complete-case approach was used for analyses by stratum and to assess interactions. Five imputations were used, based on screening 25-(OH)D strata, age, sex, and race/ethnicity. All statistical tests were 2-sided and interpreted at the 5% nominal level of significance without adjustment for multiple comparisons. Analyses were done using the FREQ, UNIVARIATE, REG, MI, and MIANALYZE procedures in SAS, version 9.2 (SAS Institute), and STRATIFY and PAIRED procedures in Proc-StatXact, version 9 (Cytel).
Role of the Funding Source
The National Institute of Allergy and Infectious Diseases funded the study. Industry sponsors (BristolMyers Squibb, Gilead Science, and Tishcon) provided antiretrovirals, vitamin D, calcium, and matching placebos, and additional funding was provided for completion of DXA scans and laboratory assays. The National Institute of Allergy and Infectious Diseases had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The manuscript was reviewed by industry sponsors before submission.
RESULTS
We enrolled 167 patients between September 2011 and February 2012 (81 in the vitamin D 3 plus calcium group and 86 in the placebo group) from 39 sites in the United States and Puerto Rico. Two patients, both from the vitamin D 3 plus calcium group, had eligibility violations because the wrong screening test was done [1,25-(OH) 2 D rather than 25-(OH)D]. At the time of discovery and while blinded to treatment group assignment and all on-study data, the protocol team decided that these patients could continue to receive study treatment but their data would not be included in efficacy analyses. Baseline demographic, immunologic, virologic, and other variables of the 165 eligible patients are summarized in Table 1 . Overall, the cohort was 90% male, 33% non-Hispanic black, 37% non-Hispanic white, and 25% Hispanic; the median CD4 cell count was 0.341 × 10 9 cells/L (interquartile range [IQR], 0.230 to 0.490); and no patients reported hepatitis B virus or hepatitis C virus co-infection. Overall, 148 (90%) patients completed study follow-up on assigned study treatment was discontinued in 9 patients in the vitamin D 3 plus calcium and 8 in the placebo group. Loss to follow-up (including relocation and incarceration) and nonadherence were the most common reasons for treatment discontinuation; in addition, 3 patients (1 in the vitamin D 3 plus calcium group and 2 in the placebo group) completed follow-up off study treatment. Twenty-five patients discontinued treatment with EFV/ FTC/TDF prematurely (13 in the vitamin D 3 plus calcium group and 12 in the placebo group). Although 48-week outcomes were unavailable for more patients in the vitamin D 3 plus calcium group than in the placebo group, reasons for missing outcomes did not seem to be related to any of the outcomes of interest ( Figure 1 ). 21 (27) 23 ( 
BMD Changes
At baseline, the median total BMD of the hip and lumbar spine for the entire cohort was 1.05 g/cm 2 (IQR, 0.96 to 1.17) and 1.11 g/cm 2 (IQR, 1.02 to 1.21), respectively, with similar distributions between groups ( Table 1) . Median Z-scores for the hip and lumbar spine were 0.00 (IQR, Ϫ0.80 to 0.50) and Ϫ0.30 (IQR, Ϫ1.20 to 0.50), respectively; distributions were similar between groups. At 48 weeks, both groups demonstrated significant decreases in total BMD of the hip from baseline (P < 0.001 for both). From baseline to 48 weeks, the percentage of decline in total BMD of the hip was smaller in the vitamin D 3 plus calcium group than in the (Figure 3) . To evaluate whether changes in BMD were related to 25-(OH)D levels, we assessed the changes in total hip BMD by screening 25-(OH)D strata: 25-(OH)D level of 25 to 50 nmol/L or 50 to 188 nmol/L. For the vitamin D 3 plus calcium group, the median decline at 48 weeks was Ϫ1.33% (IQR, Ϫ3.24% to 0.00%) in the low stratum (n = 20) and Ϫ1.48% (IQR, Ϫ3.13% to Ϫ0.66%) in the high stratum (n = 45). For the placebo group, the median decline was Ϫ2.87% (IQR, Ϫ5.20% to Ϫ1.34%) in the low stratum (n = 24) and Ϫ3.19% (IQR, Ϫ5.12% to Ϫ1.02%) in the high stratum (n = 53). Modification of the treatment effect by screening 25-(OH)D stratum was not apparent (interaction P = 0.15).
Bone Turnover Marker and PTH Level Changes
At baseline, bone turnover marker distributions were similar in the vitamin D 3 plus calcium and placebo groups for both P1NP, a bone formation marker ( . Both groups had increases in these markers at 24 and 48 weeks after ART initiation, but increases were attenuated in the vitamin D 3 plus calcium group compared with the placebo group at 24 weeks (P = 0.002 and 0.005 for P1NP and CTX, respectively) ( Figure 4 and Table 2 ). In addition, PTH levels increased 15% and 22% from baseline to 24 and 48 weeks (P ≤ 0.001 for both) in the placebo group, respectively, and a change from baseline was not apparent in the vitamin D 3 plus calcium group (1.4% [P = 0.18] and 4.3% [P = 0.17]) (between-group comparison, P < 0.011) (Figure 4) . Changes in urinary fractional excretion of phosphate from baseline to 24 or 48 weeks were not apparent in either group ( Table 2) .
Inflammatory Biomarker Changes
At baseline, the distributions of IL-6, sTNFr-I, sTNFr-II, and soluble CD14 were similar between the groups ( Table 2 ). There were no significant changes in IL-6 at 24 or 48 weeks in either group (P > 0.07 for all) or between groups at either time point (P ≥ 0.70 for both). A decline in sTNFr-I at 24 and 48 weeks was seen in the placebo group (P = 0.016 and 0.041, respectively), although changes were modest (median decrease, Ϫ64 and Ϫ62 pg/mL). There was a similar modest decline at 48 weeks (median decrease, Ϫ52 and Ϫ94 pg/mL at 24 and 48 weeks [P = 0.071 and 0.005], respectively) for the vitamin D 3 plus calcium group. However, differences in the magnitude of changes between groups The lines inside the boxes indicate the median values, the lower and upper edges of the boxes indicate the first and third quartiles (25th and 75th percentiles), and the lower and upper whiskers represent ±1.5 times IQR. Observations outside the whiskers are identified as outliers (squares). Median percentage declined significantly for both groups (P < 0.001 for both sites and groups were not apparent (P > 0.65 for both time points). Decreases in sTNFr-II were seen at 24 and 48 weeks for both treatment groups (P < 0.001 for all), but there were no differences between groups (P > 0.73 for both). Although a 17% increase in soluble CD14 from baseline to 48 weeks was seen in the vitamin D 3 plus calcium group (P = 0.008), a change was not apparent in the placebo group (5% median increase; P = 0.18); differences in the change between groups at 24 and 48 weeks were also not apparent (P > 0.16 for both).
HIV Disease Variables
Total CD4 T-cell count increased at 24 and 48 weeks in both groups (P < 0.001 for all) with no differences between groups (P ≥ 0. Table 2 ). Overall, 90% of patients achieved virologic suppression (plasma HIV RNA level <50 copies/mL) at 48 weeks; 4 patients in the vitamin D 3 plus calcium group and 10 patients in the placebo group had virologic failure (defined as >200 copies/mL confirmed with a second evaluation on or after 24 weeks).
Safety
Overall, 103 patients (62%) reported at least 1 adverse event during the study: 50 in the vitamin D 3 plus calcium group (33 patients had grade 1 to 2 events, 15 had grade 3 events, and 2 had grade 4 events) and 53 in the placebo group (33 had grade 1 to 2 events, 15 had grade 3 events, and 5 had grade 4 events). No clear pattern emerged with regard to adverse events ( Table 3 ). There were no cases of hypercalcemia and 1 case of nephrolithiasis in the placebo group. One death occurred in the vitamin D 3 plus calcium group due to renal failure in the context of rapid HIV disease progression.
DISCUSSION
Supplementation with high-dose vitamin D 3 (4000 IU) and calcium carbonate (1000 mg) with ART initiation increased 25-(OH)D levels and attenuated increases in bone turnover markers and bone loss at the hip and lumbar spine by approximately 50% at 48 weeks. These results mark the first successful intervention to attenuate bone loss with ART initiation and demonstrate the benefit of vitamin D and calcium supplementation to promote bone health in persons with HIV.
The bone loss associated with ART initiation leaves persons with HIV with lower bone mass, potentially contributing to increased fracture risk (2) (3) (4) (5) (6) (7) . With the life span of persons with HIV now approaching that of seronegative persons (47), the incidence of fragility fractures will undoubtedly increase (3, 6) . Few guidelines have addressed preventive measures in persons with HIV (48) .
Tenofovir disoproxil fumarate is associated with BMD decline (16) , not only among persons with HIV starting ART but also in seronegative persons using TDF as a component of preexposure prophylaxis and in seronegative newborns exposed to TDF in utero (49, 50) . Recent studies have explored the association among TDF bone toxicity, proximal tubule toxicity, and increased PTH levels (50). In our study, vitamin D and calcium supplementation prevented increases in PTH levels caused by ART initiation with a TDF-based regimen without altering urinary phosphate excretion, suggesting that TDF does not increase PTH levels through proximal renal tubule toxicity. Similar results were reported by Havens and colleagues (22, 23) in a study of vitamin D supplementation: PTH levels decreased with vitamin D supplementation without change in urinary phosphate excretion, and the greatest effect on PTH was seen in persons receiving TDF-containing ART. Given that PTH secretion is regulated by serum calcium, it is plausible that increased intestinal calcium absorption mediated by vitamin D is the key mechanism blocking the negative effects of TDF on BMD. Data are median percentages of increase from baseline, with error bars representing first and third quartiles (25th and 75th percentiles). Levels of P1NP and CTX increased significantly from baseline to 24 and 48 wk in both groups (P < 0.001, for all). At 24 wk, the betweengroup differences were also statistically significant (P = 0.002 for P1NP and 0.005 for CTX) but were not statistically significant at 48 wk (P > 0.088 for both). In the vitamin D 3 plus calcium group, there was no significant change in PTH levels at 24 or 48 wk (P > 0.31 for both), and the placebo group had a significant increase at 24 and 48 wk (P < 0.001 for both). The between-group differences were statistically significant for both time points (P = 0.011 at 24 wk; P = 0.004 at 48 wk). CTX = C-terminal telopeptide of type 1 collagen; P1NP = procollagen-1 N-terminal peptide; PTH = parathyroid hormone.
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Efavirenz is a potent inducer of cytochrome P450 enzymes. Several of these enzymes are involved in vitamin D metabolism, and EFV may have the detrimental off-target effect of reducing available vitamin D substrate and active metabolites (25, 51) . In contrast to previous observations, we saw only a modest, nonsignificant decline in 25-(OH)D levels at 24 weeks in the placebo group (24, 25, 52) . In the group that received vitamin D 3 plus calcium, EFV did not prevent increases in 25-(OH)D levels. We did not measure 1,25-(OH) 2 D 3 , the active metabolite, and thus cannot comment on how supplementation affected ongoing vitamin D metabolism.
Given recent data on the immunomodulatory effects of vitamin D (29, 53), we explored whether the diminished BMD loss in the vitamin D 3 plus calcium group was immune-mediated. Immune reconstitution with ART initiation may result in a surge in proresorptive cytokines and potentially explain the relatively consistent magnitude of BMD decline within the first 24 to 
ORIGINAL RESEARCH
48 weeks after initiation of ART across different regimens, as well as the more modest effect when ART is used as preexposure prophylaxis. In our study, CD14 increased in the vitamin D 3 plus calcium group, likely related to vitamin D effects on monocyte CD14 expression (30) , and TNFR levels decreased similarly from baseline to 48 weeks in both groups, likely related to virologic suppression, as previously reported (54) . The anti-inflammatory effects of ART initiation may have obscured any potential immunomodulatory effects of vitamin D. Additional research is needed to define the mechanism behind the salutary effect of vitamin D and calcium supplementation.
Our study had some limitations. We had an imbalance in the amount of missing data between groups, but a review of reasons for missing data (relocation, loss to follow-up, death, and missing or uninterpretable DXA data) did not reveal a systematic bias but rather a chance imbalance in discontinuations. Furthermore, results for our primary outcome were similar when analyzed using a multiple-imputation approach for missing data or a complete-case approach that assumed that data were missing completely at random. We followed patients for only 48 weeks and did not evaluate longerterm effects of vitamin D supplementation on fracture prevention. Data on smoking status, alcohol intake, falls, and physical activity were not collected. We could not determine whether the beneficial effect was due to vitamin D, calcium, or their combination. Our study was done in the United States and Puerto Rico, and 90% of the patients were men; thus, generalizability to other areas and women may be limited. We evaluated only 1 ART regimen (EFV/FTC/TDF); therefore, our conclusions may not be applicable to other regimens.
In summary, daily high-dose vitamin D and calcium supplementation over 48 weeks attenuates BMD decline associated with ART initiation by approximately 50%. This beneficial effect corresponded with reductions in bone turnover markers and limited excursion of PTH levels. We did not see a specific anti-inflammatory effect of vitamin D supplementation. Vitamin D and calcium supplementation is a low-cost, well-tolerated intervention to prevent ART-related bone loss. Future studies will examine alternative vitamin D doses, effects when used with other ART regimens and in international settings, and longer-term efficacy. 
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